Mary Brown
Member
Massive Bio recently completed its first strategic investment in an artificial intelligence enterprise by backing Rivvi AI. The partnership connects clinical oncology intelligence directly with automated patient engagement systems. Healthcare organizations deploy a modern healthcare communication platform to expand clinical trial access for cancer patients nationally. Consequently, integrating advanced technology accelerates recruitment workflows across complex oncology research programs.
The precision oncology leader announced this strategic investment during the Ai4 2026 conference. Rivvi AI develops agentic AI infrastructure tailored specifically for healthcare and life sciences organizations.
Both technology firms aim to improve patient identification, outreach, and clinical decision support. The joint effort combines Massive Bio's clinical intelligence with Rivvi's conversational tools.
Currently, very few eligible cancer patients participate in therapeutic clinical trials. This collaborative investment helps overcome long-standing barriers surrounding recruitment trial and care access.
Meanwhile, Rivvi provides the patient engagement layer through conversational agents that manage personalized workflows. Chief Executive Officer Selin Kurnaz noted that conversational infrastructure multiplies the value of clinical intelligence.
Co-Founder Arturo Loaiza-Bonilla emphasized that eligible patients miss trial opportunities due to communication delays. Connecting validated trial matching with consent-aware communication creates meaningful clinical capacity.
Consequently, clinical judgment remains with doctors while patients make informed choices. The automated system ensures care teams initiate vital treatment conversations at the right time.
Furthermore, personalized communication workflows help patients understand complex precision medicine choices clearly. Streamlined care management reduces administrative friction for clinical staff and participating trial sites.
As a result, health organizations match cancer patients with relevant therapeutic options faster. This strategic alliance establishes a sustainable framework for deploying artificial intelligence across oncology care networks.
Finally, integrating clinical intelligence with automated outreach transforms patient care navigation. Early identification and continuous communication improve long-term clinical trial participation rates significantly.
Discover Health Tech Insiders for the latest advancements in medical technology and trusted strategic insights shaping the future of tech-driven healthcare transformation.
Read related news - https://healthtechinsiders.com/prevent-claims-denials-before-they-happen-using-ai/
The precision oncology leader announced this strategic investment during the Ai4 2026 conference. Rivvi AI develops agentic AI infrastructure tailored specifically for healthcare and life sciences organizations.
Both technology firms aim to improve patient identification, outreach, and clinical decision support. The joint effort combines Massive Bio's clinical intelligence with Rivvi's conversational tools.
Currently, very few eligible cancer patients participate in therapeutic clinical trials. This collaborative investment helps overcome long-standing barriers surrounding recruitment trial and care access.
Connecting Clinical Intelligence With Conversational Workflows
Massive Bio operates an intelligent matching system that processes complex clinical and biomarker data. The platform discovers appropriate clinical trial opportunities for cancer patients rapidly. Tested on thousands of individuals, the system generated over seventeen thousand physician-verified matches.Meanwhile, Rivvi provides the patient engagement layer through conversational agents that manage personalized workflows. Chief Executive Officer Selin Kurnaz noted that conversational infrastructure multiplies the value of clinical intelligence.
Co-Founder Arturo Loaiza-Bonilla emphasized that eligible patients miss trial opportunities due to communication delays. Connecting validated trial matching with consent-aware communication creates meaningful clinical capacity.
Consequently, clinical judgment remains with doctors while patients make informed choices. The automated system ensures care teams initiate vital treatment conversations at the right time.
Scaling Healthcare Automation Across Modern Medical Networks
Rivvi's engagement platform has facilitated over two million interactions across half a million patients. The technology operates seamlessly across health systems, insurance payers, effectiveness, and life sciences organizations. Combining evidence-based medical intelligence with automated patient engagement creates a scalable healthcare model. Human navigators guide patients continuously through complex medical decisions following automated initial contacts.Furthermore, personalized communication workflows help patients understand complex precision medicine choices clearly. Streamlined care management reduces administrative friction for clinical staff and participating trial sites.
As a result, health organizations match cancer patients with relevant therapeutic options faster. This strategic alliance establishes a sustainable framework for deploying artificial intelligence across oncology care networks.
Finally, integrating clinical intelligence with automated outreach transforms patient care navigation. Early identification and continuous communication improve long-term clinical trial participation rates significantly.
Discover Health Tech Insiders for the latest advancements in medical technology and trusted strategic insights shaping the future of tech-driven healthcare transformation.
Read related news - https://healthtechinsiders.com/prevent-claims-denials-before-they-happen-using-ai/
